8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Feb 27, 2026·SEC
Disc Medicine, Inc.(IRON)Earnings, Financials & Key Ratios
IRON•NASDAQ
$74.78
Price updated Jun 27, 2026
AboutDisc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$236M-81.9%
- Net Income-$212M-94.0%
- EPS (Diluted)-6.01-51.8%
- ROE-35.86%-29.3%
IRON Price & Volume
Disc Medicine, Inc. (IRON) stock price & volume — 10-year historical chart
Loading chart...
Escalating Clinical Costs Threaten Long-Term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial endpoint failure
"Disc Medicine faces a challenging fundamental outlook as its R&D expenditure intensity has surged to $45.8 million in 2026Q1, significantly outpacing any potential value creation from its clinical pipeline. The failure of the AURORA trial to meet primary endpoints suggests that the company's valuation may be predicated on overly optimistic regulatory assumptions for its lead asset, bitopertin. Investors should monitor the rapid depletion of cash reserves, which have fallen from $360.4 million in 2023Q4 to $88.9 million by 2026Q1, as the firm faces persistent dilution risks from ongoing equity-based compensation and potential future financing needs."
Verdict Logic
the company's cash position has declined by approximately 75% since 2023Q4, and the failure of key clinical trial endpoints warrants extreme caution regarding the firm's long-term capital sustainability.
IRON Growth Metrics
Disc Medicine, Inc. (IRON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-107.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-69.39%
Return on Capital
10 Years-48.09%
5 Years-48.09%
3 Years-34.79%
Last Year-37.95%
IRON Recent Earnings
Disc Medicine, Inc. (IRON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.65-6.5%
$1.55
Rev
—
$437,500
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.62+4.1%
$1.69
Rev
—
$150,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.77-19.6%
$1.48
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.58-35.0%
$1.17
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.65vs $1.55-6.5% | —vs $437,500 |
| Q1 2026 | Feb 26, 2026 | $1.62vs $1.69+4.1% | —vs $150,000 |
| Q4 2025 | Nov 6, 2025 | $1.77vs $1.48-19.6% | — |
| Q3 2025 | Aug 7, 2025 | $1.58vs $1.17-35.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Disc Medicine, Inc. (IRON)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $74.78 | $2.86B | -12.44 | — | — | -35.86% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $109.84 | $7.53B | -35.32 | 45.83% | -93.84% | -204.35% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — |
Compare IRON vs Peers
Disc Medicine, Inc. (IRON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRON SEC Filings & Documents
Disc Medicine, Inc. (IRON) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IRON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRON Frequently Asked Questions
Disc Medicine, Inc. (IRON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is IRON profitable?
Disc Medicine, Inc. (IRON) reported a net loss of $241.6M for fiscal year 2025.
Dividend & Returns
What is IRON's return on equity?
Disc Medicine, Inc. (IRON) has a return on equity (ROE) of -35.9%. Negative ROE indicates the company is unprofitable.
What is Disc Medicine, Inc.'s free cash flow?
Disc Medicine, Inc. (IRON) had negative free cash flow of $201.3M in fiscal year 2025, likely due to heavy capital investments.